Enter symptom, disease type, test name or code
Use this pull down menu to view all tests offered within a disorder cateogy.
out.print(""); AdrenalAlport SyndromeAutismBartter SyndromeBone FragilityCarrier screeningCerebrovascular Disease CholesterolCongenital Blindness Congenital HyperinsulinismDementia DiabetesEpilepsy Family Cancer SyndromesFamily TestingFSGSHearing LossIntellectual disability Kidney DisordersMaturity-Onset Diabetes of the Young (MODY)MigraineMitochondrial DiseaseMonogenic HypertensionMotor Neuron DiseaseMovement Disorders Multiple Sclerosis Nephrotic syndromeNeuro-OncologyNeuromuscular Disorders ObesityPancreasParaneoplastic DisordersParathyroidParkinsonismPeripheral Neuropathy Reproductive healthRespiratory diseaseShort StatureTherapeutic Drug Monitoring X-linked Mental Retardation
Select the reference you wish to order a reprint of, and submit the form.
Sorensen PS, Deisenhammer F, Duda P, et al, for the EFNS Task Force on Treatment of Multiple Sclerosis Relapses. Guidelines on use of anti-IFN-B antibody measurements in multiple sclerosis. European Journal of Neurology 2005 12:817-827
View Abstract
Request Reprint
Giovannoni G, Goodman A, Neutralizing anti-IFN-B antibodies. How much more evidence do we need to use them in practice? . Neurology 2005 65:6-8
Vartanaian T, Sorenson P, Rice G, Impact of Neutralizing Antibodies on the Clinical Efficacy of Interferon Beta in Multiple Sclerosis. Neurology 2004, 251 S25-230
Sorenson 2003 Sorensen, P. Clinical importance of neutralizing antibodies against interferon beta in patients. The Lancet 2003; 362: 1184- 1191.
Giovannoni G, Munschauer F, Deisenhammer F Neutralizing antibodies to interferon beta during the treatment of multiple sclerosis. Journal of Neurology, Neurosurgery, & psychiatry. 2002 73:465-469
